Early intravascular events are associated with development of acute respiratory distress syndrome a substudy of the lips-A clinical trial

Raja Elie E. Abdulnour, Tina Gunderson, Ioanna Barkas, Jack Y. Timmons, Cindy Barnig, Michelle Ng Gong, Daryl J. Kor, Ognjen Gajic, Daniel Talmor, Rickey E. Carter, Bruce D. Levy

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Rationale: Acute respiratory distress syndrome (ARDS) is a devastating illness with limited therapeutic options. A better understanding of early biochemical and immunological events in ARDS could inform the development of new preventive and treatment strategies. Objectives: To determine select peripheral blood lipid mediator and leukocyte responses in patients at risk for ARDS. Methods: Patients at risk for ARDS were randomized as part of a multicenter, double-blind clinical trial of aspirin versus placebo (the LIPS-A [Lung Injury Prevention Study with Aspirin] trial; NCT01504867). Plasma thromboxane B2 (TXB2), aspirin-Triggered lipoxin A4 (15-epi-LXA4, ATL), and peripheral blood leukocyte number and activation were determined on enrollment and after treatment with either aspirin or placebo. Measurements and Main Results: Thirty-Three of 367 subjects (9.0%) developed ARDS after randomization. Baseline ATL levels, total monocyte counts, intermediate monocyte counts, and monocyte-platelet aggregates were associated with the development of ARDS. Peripheral blood neutrophil count and monocyte-platelet aggregates significantly decreased over time. Of note, nine subjects developed ARDS after randomization yet before study drug initiation, including seven subjects assigned to aspirin treatment. Subjects without ARDS at the time of first dose demonstrated a lower incidence of ARDS with aspirin treatment. Compared with placebo, aspirin significantly decreased TXB2 and increased the ATL/TXB2 ratio. Conclusions: Biomarkers of intravascular monocyte activation in at-risk patients were associated with development of ARDS. The potential clinical benefit of early aspirin for prevention of ARDS remains uncertain. Together, results of the biochemical and immunological analyses provide a window into the early pathogenesis of human ARDS and represent potential vascular biomarkers of ARDS risk.

Original languageEnglish (US)
Pages (from-to)1575-1585
Number of pages11
JournalAmerican Journal of Respiratory and Critical Care Medicine
Volume197
Issue number12
DOIs
StatePublished - Jun 15 2018
Externally publishedYes

Fingerprint

Adult Respiratory Distress Syndrome
Lip
Clinical Trials
Aspirin
Monocytes
Thromboxane B2
Placebos
Random Allocation
Platelet Count
Biomarkers
Therapeutics
Lung Injury
Leukocyte Count
Blood Vessels
Neutrophils
Leukocytes

Keywords

  • ARDS
  • Aspirin
  • Lipoxin
  • Monocyte-platelet aggregates
  • Thromboxane

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine
  • Critical Care and Intensive Care Medicine

Cite this

Early intravascular events are associated with development of acute respiratory distress syndrome a substudy of the lips-A clinical trial. / Abdulnour, Raja Elie E.; Gunderson, Tina; Barkas, Ioanna; Timmons, Jack Y.; Barnig, Cindy; Gong, Michelle Ng; Kor, Daryl J.; Gajic, Ognjen; Talmor, Daniel; Carter, Rickey E.; Levy, Bruce D.

In: American Journal of Respiratory and Critical Care Medicine, Vol. 197, No. 12, 15.06.2018, p. 1575-1585.

Research output: Contribution to journalArticle

Abdulnour, Raja Elie E. ; Gunderson, Tina ; Barkas, Ioanna ; Timmons, Jack Y. ; Barnig, Cindy ; Gong, Michelle Ng ; Kor, Daryl J. ; Gajic, Ognjen ; Talmor, Daniel ; Carter, Rickey E. ; Levy, Bruce D. / Early intravascular events are associated with development of acute respiratory distress syndrome a substudy of the lips-A clinical trial. In: American Journal of Respiratory and Critical Care Medicine. 2018 ; Vol. 197, No. 12. pp. 1575-1585.
@article{a64edd300fcc40f9a7ce435c9fedae87,
title = "Early intravascular events are associated with development of acute respiratory distress syndrome a substudy of the lips-A clinical trial",
abstract = "Rationale: Acute respiratory distress syndrome (ARDS) is a devastating illness with limited therapeutic options. A better understanding of early biochemical and immunological events in ARDS could inform the development of new preventive and treatment strategies. Objectives: To determine select peripheral blood lipid mediator and leukocyte responses in patients at risk for ARDS. Methods: Patients at risk for ARDS were randomized as part of a multicenter, double-blind clinical trial of aspirin versus placebo (the LIPS-A [Lung Injury Prevention Study with Aspirin] trial; NCT01504867). Plasma thromboxane B2 (TXB2), aspirin-Triggered lipoxin A4 (15-epi-LXA4, ATL), and peripheral blood leukocyte number and activation were determined on enrollment and after treatment with either aspirin or placebo. Measurements and Main Results: Thirty-Three of 367 subjects (9.0{\%}) developed ARDS after randomization. Baseline ATL levels, total monocyte counts, intermediate monocyte counts, and monocyte-platelet aggregates were associated with the development of ARDS. Peripheral blood neutrophil count and monocyte-platelet aggregates significantly decreased over time. Of note, nine subjects developed ARDS after randomization yet before study drug initiation, including seven subjects assigned to aspirin treatment. Subjects without ARDS at the time of first dose demonstrated a lower incidence of ARDS with aspirin treatment. Compared with placebo, aspirin significantly decreased TXB2 and increased the ATL/TXB2 ratio. Conclusions: Biomarkers of intravascular monocyte activation in at-risk patients were associated with development of ARDS. The potential clinical benefit of early aspirin for prevention of ARDS remains uncertain. Together, results of the biochemical and immunological analyses provide a window into the early pathogenesis of human ARDS and represent potential vascular biomarkers of ARDS risk.",
keywords = "ARDS, Aspirin, Lipoxin, Monocyte-platelet aggregates, Thromboxane",
author = "Abdulnour, {Raja Elie E.} and Tina Gunderson and Ioanna Barkas and Timmons, {Jack Y.} and Cindy Barnig and Gong, {Michelle Ng} and Kor, {Daryl J.} and Ognjen Gajic and Daniel Talmor and Carter, {Rickey E.} and Levy, {Bruce D.}",
year = "2018",
month = "6",
day = "15",
doi = "10.1164/rccm.201712-2530OC",
language = "English (US)",
volume = "197",
pages = "1575--1585",
journal = "American Journal of Respiratory and Critical Care Medicine",
issn = "1073-449X",
publisher = "American Thoracic Society",
number = "12",

}

TY - JOUR

T1 - Early intravascular events are associated with development of acute respiratory distress syndrome a substudy of the lips-A clinical trial

AU - Abdulnour, Raja Elie E.

AU - Gunderson, Tina

AU - Barkas, Ioanna

AU - Timmons, Jack Y.

AU - Barnig, Cindy

AU - Gong, Michelle Ng

AU - Kor, Daryl J.

AU - Gajic, Ognjen

AU - Talmor, Daniel

AU - Carter, Rickey E.

AU - Levy, Bruce D.

PY - 2018/6/15

Y1 - 2018/6/15

N2 - Rationale: Acute respiratory distress syndrome (ARDS) is a devastating illness with limited therapeutic options. A better understanding of early biochemical and immunological events in ARDS could inform the development of new preventive and treatment strategies. Objectives: To determine select peripheral blood lipid mediator and leukocyte responses in patients at risk for ARDS. Methods: Patients at risk for ARDS were randomized as part of a multicenter, double-blind clinical trial of aspirin versus placebo (the LIPS-A [Lung Injury Prevention Study with Aspirin] trial; NCT01504867). Plasma thromboxane B2 (TXB2), aspirin-Triggered lipoxin A4 (15-epi-LXA4, ATL), and peripheral blood leukocyte number and activation were determined on enrollment and after treatment with either aspirin or placebo. Measurements and Main Results: Thirty-Three of 367 subjects (9.0%) developed ARDS after randomization. Baseline ATL levels, total monocyte counts, intermediate monocyte counts, and monocyte-platelet aggregates were associated with the development of ARDS. Peripheral blood neutrophil count and monocyte-platelet aggregates significantly decreased over time. Of note, nine subjects developed ARDS after randomization yet before study drug initiation, including seven subjects assigned to aspirin treatment. Subjects without ARDS at the time of first dose demonstrated a lower incidence of ARDS with aspirin treatment. Compared with placebo, aspirin significantly decreased TXB2 and increased the ATL/TXB2 ratio. Conclusions: Biomarkers of intravascular monocyte activation in at-risk patients were associated with development of ARDS. The potential clinical benefit of early aspirin for prevention of ARDS remains uncertain. Together, results of the biochemical and immunological analyses provide a window into the early pathogenesis of human ARDS and represent potential vascular biomarkers of ARDS risk.

AB - Rationale: Acute respiratory distress syndrome (ARDS) is a devastating illness with limited therapeutic options. A better understanding of early biochemical and immunological events in ARDS could inform the development of new preventive and treatment strategies. Objectives: To determine select peripheral blood lipid mediator and leukocyte responses in patients at risk for ARDS. Methods: Patients at risk for ARDS were randomized as part of a multicenter, double-blind clinical trial of aspirin versus placebo (the LIPS-A [Lung Injury Prevention Study with Aspirin] trial; NCT01504867). Plasma thromboxane B2 (TXB2), aspirin-Triggered lipoxin A4 (15-epi-LXA4, ATL), and peripheral blood leukocyte number and activation were determined on enrollment and after treatment with either aspirin or placebo. Measurements and Main Results: Thirty-Three of 367 subjects (9.0%) developed ARDS after randomization. Baseline ATL levels, total monocyte counts, intermediate monocyte counts, and monocyte-platelet aggregates were associated with the development of ARDS. Peripheral blood neutrophil count and monocyte-platelet aggregates significantly decreased over time. Of note, nine subjects developed ARDS after randomization yet before study drug initiation, including seven subjects assigned to aspirin treatment. Subjects without ARDS at the time of first dose demonstrated a lower incidence of ARDS with aspirin treatment. Compared with placebo, aspirin significantly decreased TXB2 and increased the ATL/TXB2 ratio. Conclusions: Biomarkers of intravascular monocyte activation in at-risk patients were associated with development of ARDS. The potential clinical benefit of early aspirin for prevention of ARDS remains uncertain. Together, results of the biochemical and immunological analyses provide a window into the early pathogenesis of human ARDS and represent potential vascular biomarkers of ARDS risk.

KW - ARDS

KW - Aspirin

KW - Lipoxin

KW - Monocyte-platelet aggregates

KW - Thromboxane

UR - http://www.scopus.com/inward/record.url?scp=85049051500&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85049051500&partnerID=8YFLogxK

U2 - 10.1164/rccm.201712-2530OC

DO - 10.1164/rccm.201712-2530OC

M3 - Article

VL - 197

SP - 1575

EP - 1585

JO - American Journal of Respiratory and Critical Care Medicine

JF - American Journal of Respiratory and Critical Care Medicine

SN - 1073-449X

IS - 12

ER -